Compare CURI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CURI | MOLN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Switzerland |
| Employees | 45 | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 158.9M |
| IPO Year | N/A | 2021 |
| Metric | CURI | MOLN |
|---|---|---|
| Price | $3.34 | $4.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.83 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 376.4K | 2.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $16.90 | $285.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $3.36 |
| 52 Week High | $7.15 | $5.36 |
| Indicator | CURI | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 32.57 |
| Support Level | $3.07 | $4.02 |
| Resistance Level | $4.96 | $4.61 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 40.96 | 0.00 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.